Clinical trials have demonstrated that Provenge can extend overall survival in men with mCRPC. It offers a median survival benefit of about 4.1 months compared to placebo. Additionally, because it is a form of immunotherapy, Provenge has a different side effect profile compared to traditional treatments like chemotherapy, often resulting in fewer systemic side effects.
